The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
作者： J P Laubach , A Mahindra , C S Mitsiades , R L Schlossman , N C Munshi
DOI: 10.1038/LEU.2009.179
关键词:
摘要: Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, disease remains incurable and even who respond well to induction therapy ultimately relapse require additional treatment. Conventional chemotherapy high-dose stem cell transplantation (SCT) historically been utilized in management of relapsed MM, but recent years immunomodulatory drugs (IMiDs) thalidomide lenalidomide, as proteasome inhibitor bortezomib, assumed a primary role this setting. This review focuses on thalidomide, lenalidomide bortezomib refractory discussion dedicated emerging MM that may prove beneficial disease.
nature.com
sci-hub.se 参考文章(125)
M A Gertz, J P Garton, R A Kyle, P R Greipp, T E Witzig, A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. ,vol. 9, pp. 2115- 2118 ,(1995)
B Barlogie, R Alexanian, KA Dicke, G Zagars, G Spitzer, S Jagannath, L Horwitz, High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma Blood. ,vol. 70, pp. 869- 872 ,(1987) , 10.1182/BLOOD.V70.3.869.869
B Barlogie, R Hall, A Zander, K Dicke, R Alexanian, High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. ,vol. 67, pp. 1298- 1301 ,(1986) , 10.1182/BLOOD.V67.5.1298.1298
Alan Lichtenstein, Agnes Gardner, Yiping Tu, The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Research. ,vol. 60, pp. 6763- 6770 ,(2000)
Joseph Schoepfer, Paul A Brough, Martin J Drysdale, Michael Rugaard Jensen, Andrew Massey, Targeting Hsp90 for the treatment of cancer. Current Opinion in Drug Discovery & Development. ,vol. 9, pp. 483- ,(2006)
James R. Berenson, James R. Berenson, Steven Manyak, Steven Manyak, Amy Mikail, Amy Mikail, Evanthia Roussos, Evanthia Roussos, Mitesh J. Borad, Mitesh J. Borad, Robert A. Vescio, Robert A. Vescio, Malka Frantzen, Malka Frantzen, Kimberly Parker, Kimberly Parker, Mark H. Ma, Jason Neeser, Jason Neeser, Zhi qun Wu, Hank H. Yang, Hank H. Yang, Nelida Sjak-Shie, Nelida Sjak-Shie, Julian Adams, Cibby Altamirano, Cibby Altamirano, Jeffrey M. Friedman, Jeffrey M. Friedman, The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents Clinical Cancer Research. ,vol. 9, pp. 1136- 1144 ,(2003)
Elena Zamagni, Sonia Ronconi, Michele Cavo, Francesco Di Raimondo, Sante Tura, Claudia Cellini, Delia Cangini, Roberto Ria, Filippo Ballerini, Antonio Ledda, Angelo Vacca, Pellegrino Musto, Patrizia Tosi, Luciano Masini, Michele Baccarani, Francesco Lauria, Francesca Patriarca, Marco Gobbi, Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. ,vol. 87, pp. 408- 414 ,(2002)
Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschluter, A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology. ,vol. 132, pp. 584- 593 ,(2006) , 10.1111/J.1365-2141.2005.05914.X
I von Metzler, H Krebbel, M Hecht, R A Manz, C Fleissner, M Mieth, M Kaiser, C Jakob, J Sterz, L Kleeberg, U Heider, O Sezer, Bortezomib inhibits human osteoclastogenesis. Leukemia. ,vol. 21, pp. 2025- 2034 ,(2007) , 10.1038/SJ.LEU.2404806
Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Ling-Hua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George Muller, Peter Schafer, David Stirling, Angus G. Dalgleish, J. Blake Bartlett, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research. ,vol. 69, pp. 56- 63 ,(2005) , 10.1016/J.MVR.2005.01.002